Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Turnstone Biologics Corp. - Common Stock (NQ:TSBX)

0.3618 +0.0017 (+0.47%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Turnstone Biologics Corp. - Common Stock

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)
From Brodsky & Smith LLC
Via GlobeNewswire
TSBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Turnstone Biologics Corp. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
From XOMA Royalty Corporation; Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Announces Plans to Explore Strategic Alternatives
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Portfolio Prioritization and Corporate Restructuring Extends Cash Runway into 2Q 2026 
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Appoints William Waddill to its Board of Directors
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics to Participate in Upcoming Investor Conferences
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber
Internationally recognized thought leader with extensive experience in innovative immunotherapies for solid tumors will help guide Turnstone’s continued advancement of its Selected TIL therapies 
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update
From Turnstone Biologics Corp.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.